Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 550 participants.

Also called NCT05487950

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 550 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05487950
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05487950. Randomized; no masking; primary purpose treatment. Start 2023-04-05 (anticipated); primary completion 2027-04-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
Acronym
SHORT RUN AF
Condition
Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
Intervention (Drug)
Rivaroxaban group
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct05487950
Content hash
8018cfa33990b7a06de3fbf5ba2db0a8f6d19016b159b10670d65e3d0c6b4c3c